[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-363980-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-363980-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","targeting-lncrnas-to-overcome-cancer-therapy-resistance-advances-in-rna-therapeutics-and-delivery-strategies","Targeting lncRNAs to Overcome Cancer Therapy Resistance - Advances in RNA Therapeutics and Delivery Strategies","","Non-coding RNAs are increasingly recognized as key regulators of cancer biology, with long non-coding RNAs (lncRNAs) gaining attention for cancer-specific expression and roles in tumor progression, metastasis, and therapeutic resistance. This review summarizes how lncRNAs mediate resistance to radiotherapy, chemotherapy, immunotherapy, and targeted therapy, detailing underlying molecular mechanisms. It then discusses RNA-based therapeutics, including ASOs, siRNAs, miRNA mimics and antimiRs, and delivery platforms addressing instability, off-target effects, immune activation, clearance, and tumor-specific delivery barriers.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/targeting-lncrnas-to-overcome-cancer-therapy-resistance-advances-in-rna-therapeutics-and-delivery-strategies/363980/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/targeting-lncrnas-to-overcome-cancer-therapy-resistance-advances-in-rna-therapeutics-and-delivery-strategies/363980.png","ImageObject",300,407,{"name":42,"@type":43},"nayy☆","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why do lncRNAs attract interest in cancer therapy resistance?","Question",{"text":63,"@type":64},"Long non-coding RNAs show cancer-specific expression patterns and can actively mediate resistance by supporting cancer cell survival and adaptation under therapeutic pressure.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which cancer therapies does the review connect to lncRNA-driven resistance mechanisms?",{"text":68,"@type":64},"The review discusses resistance mechanisms against radiotherapy, chemotherapy, immunotherapy, and targeted therapy, linking lncRNAs to the underlying molecular pathways.",{"name":70,"@type":61,"acceptedAnswer":71},"What RNA-based treatment modalities are highlighted for targeting lncRNAs?",{"text":72,"@type":64},"The review focuses on antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), microRNA (miRNA) mimics and antimiRs, as well as approved RNA therapeutic agents and candidates in clinical development.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},363980,1790194574,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":102,"preview_urls":147},962090893153,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Review  \nTargeting lncRNAs to Overcome Cancer Therapy Resistance: Advances in RNA Therapeutics and Delivery Strategies  \nChristos Drosos †, Athina Kapsi †, Anthi Nikolaidou and Antonis Giakountis *  \nAcademic Editors: Suresh K. Alahari and Hengrui Liu  \nReceived: 8 June 2026  \nRevised: 28 July 2026  \nAccepted: 3 August 2026  \nPublished: 4 August 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \nDepartment of Biochemistry and Biotechnology, University of Thessaly, Biopolis, Mezourlo, 41500 Larissa, Greece * Correspondence: [agiakountis@uth.gr](agiakountis@uth.gr)  \n† These authors contributed equally to this work.  \nSimple Summary  \nCancer treatment has improved substantially over recent decades, yet many patients eventually develop resistance to therapy, limiting long-term treatment success. Increasing evidence suggests that long non-coding RNAs (lncRNAs), a class of RNA molecules that do not produce proteins, play important roles in helping cancer cells survive treatment and adapt to therapeutic pressure. These discoveries have generated interest in lncRNAs as potential therapeutic targets. At the same time, recent advances in RNA medicine have demonstrated that disease-causing RNA molecules can be successfully targeted in patients. In this review, we discuss the emerging role of lncRNAs in cancer therapy resistance and examine how advances in RNA-based treatments may create new opportunities to overcome this challenge. We also highlight key obstacles that must be addressed before lncRNAtargeted therapies can be translated into clinical practice. Improved understanding of these mechanisms may ultimately contribute to more effective and durable cancer treatments.  \nAbstract  \nNon-coding RNAs (ncRNAs) are increasingly recognized as important regulators of cancer biology. Long non-coding RNAs (lncRNAs), defined as transcripts longer than 200 nucleotides, gain particular attention due to their cancer-specific expression patterns and functional roles in tumor progression, metastasis and therapeutic resistance. Although lncRNAs have been extensively studied as diagnostic, prognostic and predictive biomarkers, growing evidence indicates that they can also act as active mediators of therapeutic resistance, supporting their potential as therapeutic candidates. Here, we summarize howlncRNAs contribute to resistance against radiotherapy, chemotherapy, immunotherapy and targeted therapy, highlighting their molecular mechanisms. Next, we discuss RNAbased therapeutics as a strategy to target disease-relevant transcripts, focusing on antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), microRNA (miRNA) mimicsand antimiRs, as well as approved RNA therapeutic agents, oncology-focused candidates in clinical development and emerging preclinical approaches directed against lncRNAsor lncRNA-controlled regulatory axes. Finally, we examine delivery platforms, including lipid-based nanovectors, extracellular vesicles, polymeric systems and other approaches designed to overcome key translational barriers, such as RNA instability, off-target effects, immune activation, renal clearance and inefficient tumor-specific delivery. By connecting lncRNA-mediated resistance mechanisms with RNA therapeutic strategies and delivery technologies, this review highlights lncRNA-directed RNA therapeutics as a promising yet developing approach in oncology.  \nKeywords: cancer; therapeutic resistance; lncRNA; RNA therapeutics; lncRNA-targeted therapy; drug delivery systems  \n1. Introduction  \nCancer remains one of the leading causes of morbidity and mortality worldwide, accounting for millions of new cases and deaths each year [1,2] . Over the past decades, major advances in early detection, molecular diagnosis and therapeutic development have improved clinical management and patient outcomes [3","cbCaiiqGfT3oHgA7","https://ap.wps.com/l/cbCaiiqGfT3oHgA7","pdf",5570416,51,"English","# 1. Introduction\n## Cancer burden and therapeutic resistance\n## Role of ncRNAs and lncRNAs in cancer biology\n# Abstract\n## Molecular mechanisms of lncRNA-mediated resistance\n## RNA-based therapeutics and delivery strategies","[{\"question\":\"Why do lncRNAs attract interest in cancer therapy resistance?\",\"answer\":\"Long non-coding RNAs show cancer-specific expression patterns and can actively mediate resistance by supporting cancer cell survival and adaptation under therapeutic pressure.\"},{\"question\":\"Which cancer therapies does the review connect to lncRNA-driven resistance mechanisms?\",\"answer\":\"The review discusses resistance mechanisms against radiotherapy, chemotherapy, immunotherapy, and targeted therapy, linking lncRNAs to the underlying molecular pathways.\"},{\"question\":\"What RNA-based treatment modalities are highlighted for targeting lncRNAs?\",\"answer\":\"The review focuses on antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), microRNA (miRNA) mimics and antimiRs, as well as approved RNA therapeutic agents and candidates in clinical development.\"}]","Targeting lncRNAs to Overcome Cancer Therapy Resistance - Advances in RNA Therapeutics and Delivery Strategies | PDF",1790154754,129,[148,152,156,160,164,168],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6484ffba70720a5e6f0531050fb52bed.webp",983,1390,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2a6a738851ec322e4102eb9ccd7f9021.webp",982,1388,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c78894ad3ac6a12b97b4e12b2f913382.webp",981,1387,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/755664acf0e33b725f3b799e9b93c8a2.webp",980,1385,{"page_no":97,"url":165,"width":166,"height":167},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/64b89e50ff3f25d1929e53dabe4f6b98.webp",979,1384,{"page_no":102,"url":169,"width":170,"height":171},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4ea7577b339e387d4f9c2ff1dd9e3263.webp",978,1383]